|
Medlive Technology Co., Ltd. (2192.HK) DCF Valuation |
- ✓ Fully Editable: Tailor To Your Needs In Excel Or Sheets
- ✓ Professional Design: Trusted, Industry-Standard Templates
- ✓ Pre-Built For Quick And Efficient Use
- ✓ No Expertise Is Needed; Easy To Follow
Medlive Technology Co., Ltd. (2192.HK) Bundle
Explore the financial prospects of Medlive Technology Co., Ltd. (2192HK) with our user-friendly DCF Calculator! Enter your assumptions regarding growth, margins, and costs to determine the intrinsic value of Medlive Technology Co., Ltd. (2192HK) and enhance your investment strategy.
Discounted Cash Flow (DCF) - (USD MM)
| Year | AY1 2019 |
AY2 2020 |
AY3 2021 |
AY4 2022 |
AY5 2023 |
FY1 2024 |
FY2 2025 |
FY3 2026 |
FY4 2027 |
FY5 2028 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 130.2 | 228.7 | 304.7 | 336.4 | 441.3 | 607.3 | 835.7 | 1,150.0 | 1,582.5 | 2,177.7 |
| Revenue Growth, % | 0.00 | 75.64 | 33.21 | 10.41 | 31.19 | 37.61 | 37.61 | 37.61 | 37.61 | 37.61 |
| EBITDA | 45.1 | 118.2 | 82.1 | 154.8 | 281.6 | 271.0 | 372.9 | 513.1 | 706.1 | 971.7 |
| EBITDA, % | 34.65 | 51.69 | 26.93 | 46.03 | 63.80 | 44.62 | 44.62 | 44.62 | 44.62 | 44.62 |
| Depreciation | 5.2 | 5.7 | 6.6 | 9.6 | 10.0 | 16.7 | 23.0 | 31.6 | 43.5 | 59.9 |
| Depreciation, % | 3.97 | 2.49 | 2.16 | 2.86 | 2.27 | 2.75 | 2.75 | 2.75 | 2.75 | 2.75 |
| EBIT | 39.9 | 112.5 | 75.5 | 145.2 | 271.5 | 254.3 | 349.9 | 481.5 | 662.6 | 911.8 |
| EBIT, % | 30.68 | 49.20 | 24.77 | 43.17 | 61.53 | 41.87 | 41.87 | 41.87 | 41.87 | 41.87 |
| Total Cash | 41.6 | 157.6 | 4,186.7 | 4,516.8 | 4,713.8 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Total Cash, percent | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables | 63.1 | 62.4 | 102.7 | 133.0 | 167.0 | 226.9 | 312.3 | 429.8 | 591.4 | 813.8 |
| Account Receivables, % | 48.47 | 27.28 | 33.70 | 39.55 | 37.84 | 37.37 | 37.37 | 37.37 | 37.37 | 37.37 |
| Inventories | 2.1 | .0 | .1 | .2 | .1 | 2.1 | 2.9 | 4.0 | 5.5 | 7.6 |
| Inventories, % | 1.62 | 0.00 | 0.03 | 0.06 | 0.02 | 0.35 | 0.35 | 0.35 | 0.35 | 0.35 |
| Accounts Payable | 2.8 | 6.7 | 6.7 | 2.9 | 15.8 | 14.3 | 19.6 | 27.0 | 37.2 | 51.2 |
| Accounts Payable, % | 2.17 | 2.93 | 2.19 | 0.86 | 3.59 | 2.35 | 2.35 | 2.35 | 2.35 | 2.35 |
| Capital Expenditure | -2.6 | -.7 | -2.1 | -8.0 | -34.8 | -16.1 | -22.1 | -30.5 | -41.9 | -57.7 |
| Capital Expenditure, % | -2.00 | -0.29 | -0.69 | -2.38 | -7.89 | -2.65 | -2.65 | -2.65 | -2.65 | -2.65 |
| Tax Rate, % | 15.29 | 18.76 | 41.99 | 13.09 | 4.27 | 18.68 | 18.68 | 18.68 | 18.68 | 18.68 |
| EBITAT | 33.8 | 91.4 | 43.8 | 126.2 | 259.9 | 206.8 | 284.5 | 391.6 | 538.8 | 741.5 |
| Depreciation | 5.2 | 5.7 | 6.6 | 9.6 | 10.0 | 16.7 | 23.0 | 31.6 | 43.5 | 59.9 |
| Changes in Account Receivables | -59.9 | -85.4 | -117.5 | -161.6 | -222.4 | |||||
| Changes in Inventories | -2.0 | -0.8 | -1.1 | -1.5 | -2.1 | |||||
| Changes in Accounts Payable | -1.5 | 5.3 | 7.4 | 10.2 | 14.0 | |||||
| Capital Expenditure | -2.6 | -0.7 | -2.1 | -8.0 | -34.8 | -16.1 | -22.1 | -30.5 | -41.9 | -57.7 |
| UFCF | -26.1 | 103.2 | 7.9 | 93.5 | 214.2 | 143.9 | 204.5 | 281.6 | 387.5 | 533.1 |
| WACC, % | 6.92 | 6.92 | 6.92 | 6.92 | 6.92 | 6.92 | 6.92 | 6.92 | 6.92 | 6.92 |
| PV UFCF | 134.6 | 178.9 | 230.3 | 296.5 | 381.5 | |||||
| SUM PV UFCF | 1,221.8 | |||||||||
| Long Term Growth Rate, % | 3.50 | |||||||||
| Free cash flow (T + 1) | 551.8 | |||||||||
| Terminal Value | 16,133.3 | |||||||||
| Present Terminal Value | 11,545.9 | |||||||||
| Enterprise Value | 12,767.7 | |||||||||
| Net Debt | -4,659.0 | |||||||||
| Equity Value | 17,426.7 | |||||||||
| Diluted Shares Outstanding, MM | 735.0 | |||||||||
| Equity Value Per Share | 23.71 |
What You Will Receive
- Customizable Excel Template: A fully editable Excel-based DCF Calculator featuring pre-populated financial data for Medlive Technology Co., Ltd. (2192HK).
- Accurate Data: Access to historical performance data and forward-looking projections (highlighted in the yellow cells).
- Flexible Forecasting: Adjust key assumptions such as revenue growth, EBITDA margin, and WACC at your convenience.
- Instant Calculations: Quickly evaluate how your input changes affect Medlive's valuation.
- Professional Resource: Designed for investors, CFOs, consultants, and financial analysts alike.
- Intuitive Layout: Organized for simplicity and ease of navigation, complete with step-by-step guidelines.
Key Features
- 🔍 Real-Life Medlive Technology Financials: Pre-filled historical and projected data for Medlive Technology Co., Ltd. (2192HK).
- ✏️ Fully Customizable Inputs: Modify all essential parameters (yellow cells) including WACC, growth %, and tax rates.
- 📊 Professional DCF Valuation: Integrated formulas calculate Medlive's intrinsic value using the Discounted Cash Flow method.
- ⚡ Instant Results: View Medlive's valuation immediately after adjustments are made.
- Scenario Analysis: Evaluate and contrast outcomes for different financial assumptions side-by-side.
How It Works
- Step 1: Download the Excel file for Medlive Technology Co., Ltd. (2192HK).
- Step 2: Explore the pre-filled financial data and forecasts for Medlive Technology Co., Ltd. (2192HK).
- Step 3: Adjust key variables such as revenue growth, WACC, and tax rates (highlighted cells) for Medlive Technology Co., Ltd. (2192HK).
- Step 4: Observe real-time updates to the DCF model as you modify your assumptions for Medlive Technology Co., Ltd. (2192HK).
- Step 5: Examine the results and leverage them for informed investment decisions regarding Medlive Technology Co., Ltd. (2192HK).
Why Choose This Calculator for Medlive Technology Co., Ltd. (2192HK)?
- User-Friendly Interface: Tailored for both novice users and seasoned professionals.
- Customizable Inputs: Modify assumptions easily to suit your analytical needs.
- Real-Time Updates: Observe immediate changes to Medlive’s valuation as you adjust your parameters.
- Pre-Loaded Data: Comes with Medlive’s current financial figures for swift evaluations.
- Preferred by Experts: Utilized by investors and analysts for making well-informed choices.
Who Can Benefit from Medlive Technology Co., Ltd. (2192HK)?
- Investors: Empower your investment choices with a robust valuation tool tailored for the healthcare technology sector.
- Financial Analysts: Streamline your analysis process with a customizable DCF model designed specifically for Medlive Technology.
- Consultants: Efficiently modify the template for engaging client presentations and comprehensive reports on Medlive's performance.
- Finance Enthusiasts: Enhance your knowledge of valuation methods through practical, industry-specific case studies involving Medlive Technology.
- Educators and Students: Utilize this resource as a hands-on learning aid for finance courses related to technology and healthcare.
Overview of the Template Features
- Pre-Filled DCF Model: Financial data for Medlive Technology Co., Ltd. (2192HK) preloaded for immediate application.
- WACC Calculator: Comprehensive calculations for the Weighted Average Cost of Capital.
- Financial Ratios: Assess Medlive’s profitability, leverage, and operational efficiency.
- Editable Inputs: Modify assumptions such as growth rates, profit margins, and capital expenditures to align with your scenarios.
- Financial Statements: Access annual and quarterly reports to enhance detailed analysis.
- Interactive Dashboard: Effortlessly visualize essential valuation metrics and results.
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.